Health
Multi-center Phase I study of anti-VISTA opens for patient enrollment – News-Medical.Net
Dartmouth and Dartmouth-Hitchcock Norris Cotton Cancer Center will serve as one of the lead institutions for a new multi-center clinical trial of anti-VISTA, no…
Reviewed by Emily Henderson, B.Sc.Oct 7 2020
Dartmouth and Dartmouth-Hitchcock Norris Cotton Cancer Center (NCCC) will serve as one of the lead institutions for a new multi-center clinical trial of anti-VISTA, now open and recruiting for patient enrollment. The trial is a Phase I study of CI-8993, an anti-VISTA (V-domain Ig Suppressor of T-cell Activation) antibody, in adult patients with advanced solid tumors.
VISTA is a checkpoint regulator whose function is to prevent activation of the immu…
-
General16 hours agoQantas terminal at Melbourne Airport evacuated and flights delayed due to fire
-
Business23 hours ago$10,000 invested in Woodside shares 4 years ago is now worth…
-
Business21 hours ago3 of the best ASX ETFs for beginners to buy with $1,000
-
Noosa News24 hours agoDairy ‘disrupter’ wins science award for inventing spreadable butter in 1970s